Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811(sc) in solid tumors
NCT07275242Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of trastuzumab rezetecan in solid tumor (3 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Area under the curve from time zero to 21 days, Dose-Limiting Toxicities at 72 weeks and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07275242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275242.